Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic HCT
Corey Cutler(Harvard University), Joseph H. Antin(Dana-Farber Cancer Institute), Margaret L. MacMillan(University of Minnesota Medical Center), Brent R. Logan(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Zhen‐Huan Hu(Medical College of Wisconsin), Laura Johnston(City Of Hope National Medical Center), Sung Won Choi(University of Michigan), Philip L. McCarthy(Roswell Park Comprehensive Cancer Center), Stephan A. Grupp(Children's Hospital of Philadelphia), William J. Hogan(Mayo Clinic), Ryotaro Nakamura(City Of Hope National Medical Center), Marcelo C. Pasquini(Cleveland Clinic), Mary M. Horowitz(Medical College of Wisconsin), David Porter(University of Pennsylvania), Juan Wu(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Shelly L. Carter(Emmes (United States)), Jack W. Hsu(University of Florida Health), Edmund K. Waller(Emory University)
Cited by 218
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
The Complement Inhibitor Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
|New England Journal of Medicine|2006|1.3k